Alkermes Stock News

Alkermes plc''s (NASDAQ: ALKS ) ENLIGHTEN-Early Phase 3b study of Lybalvi (olanzapine & samidorphan) met its prespecified primary endpoint on body weight in young schizophrenia adult patients in the early stage of the disease. Patients treated with Lybalvi experienced statistically significantly less weight gain than patients treated with olanzapine at Week 12 (6.77% for olanzapine vs. 4.91% for Lybalvi). Lybalvi is … Full story available on Benzinga.com

Here's a roundup of top developments in the biotech space over the last 24 hours: Stocks In Focus Axsome To Pay $312,500 To Settle Patent Infringement Litigation With Baudax Axsome Therapeutics, Inc.

Alkermes (ALKS) is trading ~6% higher on Monday after the company announced topline results from its ENLIGHTEN-Early trial suggesting the Phase 3 study for the schizophrenia therapy…

Alkermes plc's ALKS ENLIGHTEN-Early Phase 3b study of Lybalvi (olanzapine & samidorphan) met its prespecified primary endpoint on body weight in young schizophrenia adult patients in the early stag

How do you pick the next stock to invest in? One way would be to spend days of research browsing through thousands of publicly traded companies.

Alkermes (ALKS) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Alkermes (ALKS) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Techne (TECH) delivered earnings and revenue surprises of 3.30% and 0.84%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the stock?

Epizyme (EPZM) to issue secondary shares, which will significantly dilute its current shareholder base. Consequently, share price declines.

BridgeBio (BBIO) doses the first patient in a phase I/II study evaluating its investigational gene therapy candidate, BBP-631, for treating classic congenital adrenal hyperplasia.

The FDA bestows an Orphan Drug status to ALX Oncology's (ALXO) lead candidate, evorpacept, for treating gastric cancer and gastroesophageal junction cancer.

Biogen (BIIB) is selling its equity stake in the Samsung Bioepis joint venture to partner Samsung Biologics

Alkermes <> was upgraded by Cantor Fitzgerald to Overweight from Neutral with a price target of $32, up from $28.Cantor Fitzgerald analyst Brandon Folkes said that in an

Moderna (MRNA) doses the first participant in a phase II study on its Omicron specific COVID-19 booster candidate in a mid-stage study.

Vertex Pharmaceuticals' (VRTX) earnings and sales surpass estimates for the fourth quarter of 2021. The company provides its revenue guidance for 2022.